Is ibrutinib-related atrial fibrillation dose dependent? Insights from an individual case level analysis of the World Health Organization pharmacovigilance database.
Journal
Leukemia
ISSN: 1476-5551
Titre abrégé: Leukemia
Pays: England
ID NLM: 8704895
Informations de publication
Date de publication:
19 Sep 2024
19 Sep 2024
Historique:
received:
02
07
2024
accepted:
13
09
2024
revised:
12
09
2024
medline:
20
9
2024
pubmed:
20
9
2024
entrez:
19
9
2024
Statut:
aheadofprint
Résumé
Whether ibrutinib-related atrial fibrillation (IRAF) is a dose-dependent adverse drug reaction (ADR) and whether ibrutinib should be discontinued or dose-reduced in case of IRAF occurrence remains unknown. Using the World Health Organization individual case safety report pharmacovigilance database, VigiBase®, we aimed to determine the association between ibrutinib dosing regimens and IRAF reporting. Ibrutinib daily dose was extracted from IRAF cases from VigiBase® and was divided into 5 ibrutinib dosing regimen (140-280-420-560 and >560 mg/day). Disproportionality analysis was used to evaluate the association between IRAF reporting and ibrutinib daily dose, through logistic regression. Single term deletions produced the ibrutinib daily dose global p-value. Then, a multivariable adjusted reporting odds-ratio with its 95% confidence interval was calculated for each ibrutinib dosing regimen, against the lowest dosing regimen (140 mg/day) as reference. A total of 1162 IRAF cases were identified in VigiBase® (n = 62 for ibrutinib 140 mg/day, 114 for ibrutinib 280 mg/day, 811 for ibrutinib 420 mg/day, 164 for ibrutinib 560 mg/day and 11 for ibrutinib >560 mg/day). After adjustment on several variables of interest, IRAF reporting was not significantly associated with ibrutinib dosing regimen (p = 0.09). Our results from Vigibase® do not support IRAF as a dose-dependent ADR (ClinicalTrial registration number: NCT06224452).
Identifiants
pubmed: 39300222
doi: 10.1038/s41375-024-02413-5
pii: 10.1038/s41375-024-02413-5
doi:
Banques de données
ClinicalTrials.gov
['NCT06224452']
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s).
Références
Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Döhner H, et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018;131:2745–60.
doi: 10.1182/blood-2017-09-806398
pubmed: 29540348
Leong DP, Caron F, Hillis C, Duan A, Healey JS, Fraser G, et al. The risk of atrial fibrillation with ibrutinib use: a systematic review and meta-analysis. Blood. 2016;128:138–40.
doi: 10.1182/blood-2016-05-712828
pubmed: 27247135
Alexandre J, Boismoreau L, Morice PM, Sassier M, Da-Silva A, Plane AF, et al. Atrial Fibrillation Incidence Associated With Exposure to Anticancer Drugs Used as Monotherapy in Clinical Trials. JACC CardioOncol. 2023;5:216–26.
doi: 10.1016/j.jaccao.2022.11.019
pubmed: 37144106
pmcid: 10152197
Baptiste F, Cautela J, Ancedy Y, Resseguier N, Aurran T, Farnault L, et al. High incidence of atrial fibrillation in patients treated with ibrutinib. Open Heart. 2019;6:e001049.
doi: 10.1136/openhrt-2019-001049
pubmed: 31168393
pmcid: 6519413
Dickerson T, Wiczer T, Waller A, Philippon J, Porter K, Haddad D, et al. Hypertension and incident cardiovascular events following ibrutinib initiation. Blood. 2019;134:1919–28.
doi: 10.1182/blood.2019000840
pubmed: 31582362
pmcid: 6887116
Wu H, Wang W, Liu F, Weisberg EL, Tian B, Chen Y, et al. Discovery of a potent, covalent BTK inhibitor for B-cell lymphoma. ACS Chem Biol. 2014;9:1086–91.
doi: 10.1021/cb4008524
pubmed: 24556163
pmcid: 4027949
Xiao L, Salem JE, Clauss S, Hanley A, Bapat A, Hulsmans M, et al. Ibrutinib-Mediated Atrial Fibrillation Due to Inhibition of CSK. Circulation. 2020;142:2443–55.
doi: 10.1161/CIRCULATIONAHA.120.049210
pubmed: 33092403
pmcid: 9661397
Buck B, Chum AP, Patel M, Carter R, Nawaz H, Yildiz V, et al. Cardiovascular Magnetic Resonance Imaging in Patients With Ibrutinib-Associated Cardiotoxicity. JAMA Oncol. 2023;9:552–5.
doi: 10.1001/jamaoncol.2022.6869
pubmed: 36729480
pmcid: 9896369
EMA. European Medicines Agency. 2018. Imbruvica. Disponible sur: https://www.ema.europa.eu/en/medicines/human/EPAR/imbruvica
Quartermaine C, Ghazi SM, Yasin A, Awan FT, Fradley M, Wiczer T, et al. Cardiovascular Toxicities of BTK Inhibitors in Chronic Lymphocytic Leukemia: JACC: CardioOncology State-of-the-Art Review. JACC CardioOncol. 2023;5:570–90.
doi: 10.1016/j.jaccao.2023.09.002
pubmed: 37969643
pmcid: 10635896
Thompson PA, Lévy V, Tam CS, Al Nawakil C, Goudot FX, Quinquenel A, et al. Atrial fibrillation in CLL patients treated with ibrutinib. An international retrospective study. Br J Haematol. 2016;175:462–6.
doi: 10.1111/bjh.14324
pubmed: 27611233
Singh A, El Hangouche N, McGee K, Gong FF, Lentz R, Feinglass J, et al. Utilizing left atrial strain to identify patients at risk for atrial fibrillation on ibrutinib. Echocardiography. 2021;38:81–8.
doi: 10.1111/echo.14946
pubmed: 33594858
Brown JR, Moslehi J, O’ Brien S, Ghia P, Hillmen P, et al. Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials. Haematologica. 2017;102:1796–805.
doi: 10.3324/haematol.2017.171041
pubmed: 28751558
pmcid: 5622864
Alexandre J, Salem JE, Moslehi J, Sassier M, Ropert C, Cautela J, et al. Identification of anticancer drugs associated with atrial fibrillation: analysis of the WHO pharmacovigilance database. Eur Heart J Cardiovasc Pharmacother. 2021;7:312–20.
doi: 10.1093/ehjcvp/pvaa037
pubmed: 32353110
Faillie JL. Case-non case studies: Principles, methods, bias and interpretation. Therapie. 2018;73:247–55.
Sarosiek S, Gustine JN, Flynn CA, Leventoff C, Little M, White T, et al. Dose reductions in patients with Waldenström macroglobulinaemia treated with ibrutinib. Br J Haematol. 2023;201:897–904.
doi: 10.1111/bjh.18643
pubmed: 36626914
Chen H, Cohen P, Chen S. How Big is a Big Odds Ratio? Interpreting the Magnitudes of Odds Ratios in Epidemiological Studies. Commun Stat Simul Comput. 2010;39:860–4.
doi: 10.1080/03610911003650383
Jiang L, Li L, Ruan Y, Zuo S, Wu X, Zhao Q, et al. Ibrutinib promotes atrial fibrillation by inducing structural remodeling and calcium dysregulation in the atrium. Heart Rhythm. 2019;16:1374–82.
doi: 10.1016/j.hrthm.2019.04.008
pubmed: 30959203
Isaza N, Bolen MA, Griffin BP, Popović ZB. Functional Changes in Acute Eosinophilic Myocarditis Due to Chemotherapy With Ibrutinib. CASE. 2019;3:71–6.
doi: 10.1016/j.case.2018.11.001
pubmed: 31049484
pmcid: 6480292
Kaptein A, De Bruin G, Emmelot-van Hoek M, Van De Kar B, De Jong A, Gulrajani M, et al. Potency and Selectivity of BTK Inhibitors in Clinical Development for B-Cell Malignancies. Blood. 2018;132:1871.
doi: 10.1182/blood-2018-99-109973
Patel V, Balakrishnan K, Bibikova E, Ayres M, Keating MJ, Wierda WG, et al. Comparison of Acalabrutinib, A Selective Bruton Tyrosine Kinase Inhibitor, with Ibrutinib in Chronic Lymphocytic Leukemia Cells. Clin Cancer Res. 2017;23:3734–43.
doi: 10.1158/1078-0432.CCR-16-1446
pubmed: 28034907
Brown JR, Byrd JC, Ghia P, Sharman JP, Hillmen P, Stephens DM, et al. Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy: pooled analysis of 762 patients. Haematologica. 2022;107:1335–46.
doi: 10.3324/haematol.2021.278901
pubmed: 34587719
Andrade J, Khairy P, Dobrev D, Nattel S. The clinical profile and pathophysiology of atrial fibrillation: relationships among clinical features, epidemiology, and mechanisms. Circ Res. 2014;114:1453–68.
doi: 10.1161/CIRCRESAHA.114.303211
pubmed: 24763464
Tuomi JM, Xenocostas A, Jones DL. Increased Susceptibility for Atrial and Ventricular Cardiac Arrhythmias in Mice Treated With a Single High Dose of Ibrutinib. Can J Cardiol. 2018;34:337–41.
doi: 10.1016/j.cjca.2017.12.001
pubmed: 29475534
Tuomi JM, Bohne LJ, Dorey TW, Jansen HJ, Liu Y, Jones DL, et al. Distinct Effects of Ibrutinib and Acalabrutinib on Mouse Atrial and Sinoatrial Node Electrophysiology and Arrhythmogenesis. J Am Heart Assoc. 2021;10:e022369.
doi: 10.1161/JAHA.121.022369
pubmed: 34726066
pmcid: 8751944
Lyon AR, López-Fernández T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS): Developed by the task force on cardio-oncology of the European Society of Cardiology (ESC). Eur Heart J. 2022;43:4229–361.
doi: 10.1093/eurheartj/ehac244
pubmed: 36017568
Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2021;42:373–498.
doi: 10.1093/eurheartj/ehaa612
pubmed: 32860505
Font J, Milliez P, Ouazar AB, Klok FA, Alexandre J. Atrial fibrillation, cancer and anticancer drugs. Arch Cardiovasc Dis. 2023;116:219–26.
doi: 10.1016/j.acvd.2023.02.005
pubmed: 37002156
Halcox JPJ, Wareham K, Cardew A, Gilmore M, Barry JP, Phillips C, et al. Assessment of Remote Heart Rhythm Sampling Using the AliveCor Heart Monitor to Screen for Atrial Fibrillation: The REHEARSE-AF Study. Circulation. 2017;136:1784–94.
doi: 10.1161/CIRCULATIONAHA.117.030583
pubmed: 28851729
Common Terminology Criteria for Adverse Events (CTCAE) | Protocol Development | CTEP. 2024. Disponible sur: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm#ctc_50 .
Williams AM, Baran AM, Casulo C, Reagan P, Friedberg JW, Helber M, et al. Ibrutinib Dose Adherence and Therapeutic Efficacy in Non-Hodgkin Lymphoma: A Single-Center Experience. Clin Lymphoma Myeloma Leuk. 2019;19:41–7.
doi: 10.1016/j.clml.2018.10.005
pubmed: 30409718
Narezkina A, Lu X, Emond B, Côté-Sergent A, Hilts A, Liu S, et al. Real-World Persistence and Time to Next Treatment with Ibrutinib Treatment in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Including Patients at High Risk for Atrial Fibrillation or Stroke. Blood. 2021;138:4112.
doi: 10.1182/blood-2021-148640
Prada-Ramallal G, Takkouche B, Figueiras A. Bias in pharmacoepidemiologic studies using secondary health care databases: a scoping review. BMC Med Res Methodol. 2019;19:53.
doi: 10.1186/s12874-019-0695-y
pubmed: 30871502
pmcid: 6419460